Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Given Average Recommendation of “Buy” by Analysts

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) have been given an average recommendation of “Buy” by the six analysts that are presently covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $48.00.

A number of brokerages have weighed in on AAPG. Rodman & Renshaw initiated coverage on Ascentage Pharma Group International in a report on Tuesday, January 13th. They issued a “buy” rating and a $48.00 target price for the company. BTIG Research restated a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a report on Thursday, March 26th. Finally, Lucid Cap Mkts upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, December 15th.

Institutional Investors Weigh In On Ascentage Pharma Group International

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Hsbc Holdings PLC acquired a new position in shares of Ascentage Pharma Group International during the second quarter valued at about $391,000. Tema Etfs LLC acquired a new stake in shares of Ascentage Pharma Group International in the 2nd quarter valued at about $610,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in Ascentage Pharma Group International in the 3rd quarter valued at about $96,000. ABC Arbitrage SA acquired a new position in Ascentage Pharma Group International during the 3rd quarter worth approximately $204,000. Finally, UBS Group AG raised its stake in Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after buying an additional 10,988 shares during the period.

Ascentage Pharma Group International Trading Up 0.3%

Shares of AAPG opened at $27.41 on Monday. The company has a quick ratio of 1.77, a current ratio of 1.79 and a debt-to-equity ratio of 0.57. The firm’s fifty day simple moving average is $23.94 and its two-hundred day simple moving average is $29.25. Ascentage Pharma Group International has a 12 month low of $17.56 and a 12 month high of $48.45.

Ascentage Pharma Group International (NASDAQ:AAPG) last posted its quarterly earnings data on Wednesday, March 25th. The company reported ($0.52) earnings per share for the quarter. The firm had revenue of $24.72 million during the quarter.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.